PubMed:32178765 / 1267-1526 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T9 0-259 Sentence denotes Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.
T9 0-259 Sentence denotes Patients were randomly assigned (1:1:1, computer-generated permuted blocks; stratified by baseline DMARD and previous TNF inhibitor use) to subcutaneous guselkumab 100 mg every 4 weeks; guselkumab 100 mg at weeks 0, 4, then every 8 weeks; or matching placebo.

yaoziqian_800_3

Id Subject Object Predicate Lexical cue
T10 251-258 CI denotes placebo
T8 153-163 CI denotes guselkumab
T9 186-196 CI denotes guselkumab

Zierdiyeerkenaili_800_3

Id Subject Object Predicate Lexical cue
T10 153-163 CI denotes guselkumab
T11 186-196 CI denotes guselkumab
T18 251-258 CI denotes placebo